We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Most PIs look at the numbers (revenue, dividend yield, etc...) and that biases their view of the company. They pay too much attention to the day-to-day or hour-to-hour movements of the share price, which is in turn influenced largely by other PIs.
But the biggest indicator of the company's value and future prospects is a section without bottom-line numbers attached to it. Have a re-read of this and then think why the company included it in the results:
• Value proposition for human challenge trials has been reinforced by recent positive outcomes:
• Pfizer's ABRYSVO™ became one of the first RSV vaccines to receive FDA approval in May 2023 having received Breakthrough Designation, following an PII HCT conducted by hVIVO
• At least two biotech clients received FDA Fast Track and/or Breakthrough Designation
And couple that with this statement:
• Upcoming move to the new state-of-the-art facility, which is largely funded by key clients, will increase revenue potential and position the Company for further margin improvements
If you know anything about biomedical research, you'll know how much time, money and other resources are spent on developing pipelines of medicines. And if hVivo are able to showcase that (so far) 3 clients have received Fast Track or Breakthrough Designations following data generated using hVivo's unique offering, then that is going to have huge ramifications for other biotech companies.
We can already see how important this is, in the second statement I highlighted. The new facility was *largely funded by key clients*. I challenge any PI here to show me another example of this happening.
There is a huge demand for hVivo's unique offering, by companies with very deep pockets.
Sure, sell out at 29p and try to time the market getting back in. Sure, complain that the dividend is 0.2p instead of 1p. But I guarantee that the IIs who were desperate to get in at 28p won't be reading today's RNS with the same focus that PIs are.
It's difficult to beat guidance if you set it too high.
MOA - Under promise, over deliver.
Maybe they have an acquisition in mind and need to preserve cash.
Id10t, the view/narrative is the dividend is required as a tickbox for institutions and so beings the yearly pay out
Agreed, would have expected a bit more revenue but at least it's an increase compared to previous year.
It's a relatively no surprises set of results - strong and consistent. And I would expect a churn in the stock as a positive.
DYOR
I think the revenue target of £62m, following last years £60m, is a bit weak. A 10% increase to £66m would be challenging and still in growth territory. Yes £100m by 2028 is excellent but following the move this qtr, more contracts would be very welcome IMHO.
GLA
Considering the growing cash pile and how long they have held on to it, it's no wonder the market has marked us down.
My personal view is that this is not worth doing, either make it 1p or don't bother!
Thanks Strictly. That was one of my thoughts as I'm stuck between a rock and a hard place and couldn't risk a drop. Good to see there are still some decent folk on here
AIM stock, general market sentiment, news already baked into SP, profit taking...
DYOR
A lot of the information was in the open so its the expected churn when something materially higher wasn't announced.
The final higher EBITDA was higher than given at the last TU.
Also the dividend was higher than I expected (0.2p, I thought 0.1p).
Cavendish upped their pt to 40p:
"Our 2024 estimates have been upgraded, EBITDA increasing 3% and cash generation up 5%. We increase our target price from 38p to 40p on our forecast upgrades. "
Really thought this would rise after such excellent results. Also surprised at number of sales of such a successful and growing company . The London stock market is just not a good place to be compared to the USA. I feel the likelihood of this company at some stage being bought out is very high if the valuation persists.
Well done NST - at least you times your sells before todays fall!!
These are excellent results, good cash position and an encouraging dividend payment. Mo Khan gave a very positive interview this morning. A positive future awaits.
Excellent performance well done team LH&K Mafuta
I like this bit a lot.
"Our current £80 million weighted orderbook is highly diversified, with work contracted across 7 challenge agents and 11 HCT clients, substantially reducing the impact to hVIVO of potential postponements or cancellations."
Overall a very strong performance. As expected.
EBITDA margins of 23.3%. Fantastic as only advised 22% in trading update a couple of months ago!!
The most interesting thing is canary wharf is up and running this month! I didnt expect that. Everything else as predicted and rock solid
Just thinking the same thing !
Https://www.londonstockexchange.com/news-article/HVO/final-results/16413590
Where's the results RNS?
Still waiting for stts big predictions, he said cash would be down but too scared to name a figure?
I'll go 40m cash now ;)
Which one is your/BillB/Moniman/ reasoning for deramping TLY then?
Forgot number 4) lazy retaliation for cretins
"sp is being manipulated lower"
Haha yeah right, typical vacuous last resort sentence by desperate posters.
"Do you not support companies who help those who need help with their health?"
Couldn't care less. Owning shares in a company is not showing any sort of moral support for a company, it is business, not ethics.
"Why not just load up and sit back instead of being rattled that you had to post such a long post late Friday night?"
The most ironic thing for a man who's sat on the bulletin board of a company he doesn't own for YEARS and written thousands of lengthy posts; one of if not the most rattled person I've ever seen on Lse.
"If you could counter what I've been saying with any kind of cogent, rational argument you would have by now"
I tired, a number of times in fact, every single time u were took scared to engage me and either totally ignored the messages or tweaked your little list.
"TLY is an illiquid share and is only 1 of many shares I comment on."
Stt posts this month
TLY 10
TW 2
Byotrol 3
PSN 5
... HVO 46(!)
So no, you don't comment on "many shares" and given the sheer volume and length of time youve been posting on TLY it's clear it's 90, maybe even 100% of your portfolio so it's clear to see what's got you so "rattled". Bought in on hype, lost out, then missed out when hype turned into mature, profitable company and can't live with the fact the decisions you made were your own and no one else's fault.
Forgot to mention Cathal Friel still has largest personal shareholding in the company 21,159,177 shares or over 3% of the company, far more than a 'Red Flag' troll that I could mention but won't in case the attention gets the sad troll excited. JMO
Oh dear more green boxes just appeared that can only be from, our #1 resident troll..Mr Red Flag? 🤔? 40p by the end of year I'm guessing:
Canary Wharf facilities get fully utilised with big pharma clients queueing up to use larger state of art facilities that they paid for!!!
£100 million turnover target won't be too hard to achieve in the next couple of years it would appear?
Cash pile well in excess of £30 million at last count is some achievement considering the company had almost zero cash about 4 years ago.
New Challenge studies being offered to clients to tackle more viruses with potential for significant increase in revenues and big pharma clients from across the globe.
Fair play to Cathal and Mo for revamping the business into the number 1 player in the field globally. A real UK success story with support from top 5 international pharmaceutical companies and government backing. The moat around Hvivo is amazing for the size of the business and competition is almost zero in this highly specialised and regulated business. Aimho Adyor GLA!!!